Thus, the possibility to efficiently inhibit neovascularization in vivo by using an inhibitor specifically directed against a single AGF is far-off [214], while “multivalent” polyanionic drugs (able to bind different AGFs) may be more effective in inhibiting angiogenesis and consequent tumor progression in vivo. The gene discussed is ANGPTL6; the disease is neoplasm.